STC2 and neoplasm: Furthermore, STC2 knockdown 6-10B and CNE1 cells were more sensitive to cisplatin treatment (Fig. 3b), displaying a significantly reduced IC50 of cisplatin, compared to the its control cells (Fig. 3b), suggesting the enhanced anti-tumor effect for chemotherapeutic treatment upon STC2 silencing (6-10B control IC50=5.2μM, 6-10B shSTC2-1 IC50=2.74μM, 6-10B shSTC2-2 IC50=2.9μM, CNE1 control IC50=2.14μM, CNE1 shSTC2-1 IC50=1.46μM, CNE1 shSTC2-2 IC50=1.48μM).